Back to Agenda
[S12] What is Expected to MA/MSL?
Session Chair(s)
Yasuyuki Katayama, MD, PhD
Corporate Officer, Country Medical Director and Head of Medical Japan
Pfizer Japan Inc., Japan
Many pharmaceutical companies are reinforcing function of Medical affairs in recent years. In particular, MA/MSL are the core function within medical activity and they have various responsibilities or skills. Also, some groups of pharmaceutical industry made a statement about role or responsibility of MA/MSL. In this session, speakers from academia, pharmaceutical companies and regulatory authority will share their perspective on expectation to MA/MSL. The workshop is designed to discuss what is expected to MA/MSL with participants. D ring this workshop, we will be able to identify common sense or gaps about role of MA/MSL among pharmaceutical industry groups and to clarify position or responsibility of MA/MSL in Japan.
Speaker(s)
What is Medical Affairs or Medical Science Liaison? -Questions from Medical Doctor-
Toshiya Nishibe, MD, PhD
Tokyo Medical University, Japan
Professor, Department of Cardiovascular Surgery
How MA/MSL Should Be?
Takamasa Horio, JD
Ministry of Health, Labour and Welfare (MHLW), Japan
Legal Advisor, Compliance and Narcotics Division
Consensus Statement on MA / MSL activities
Takeshi Nishimura, PhD
Sumitomo Dainippon Pharma Co., Ltd., Japan
Senior Director, Medical Affairs Regional Function Head
How MA/MSL Good Look Like? – PhRMA Perspective-
Takeshi Imaoka, MD, PhD
Eli Lilly Japan K.K., Japan
Senior Director, Database Research Medicine Development Unit
Have an account?